keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day One - CST/CDT (Central Daylight, GMT-5)
keyboard_arrow_leftSearch & Filter
search
Free / Premium
Day One - CST/CDT (Central Daylight, GMT-5)
search
Free / Premium
Showing 1 of 1 Streams
General Session
7:30am - 8:45am
Breakfast and Networking
8:45am - 9:00amFree
Chairman's Opening and Welcome Remarks
- Matthew Gibbs, Pharm.D., Independent Consultant
9:00am - 9:45amFree
Regulatory Update: The Changing Legal Environment in HealthCare
PBM Transparency Act of 2023
- Update: PBM Transparency Act of 2023 (FTC Investigation)
- What are the ramifications to come out of the transparency act?
- How is everyone doing business? State by state differentials
- Fully understanding the house energy committee's objectives
Continued insights on:
- Consolidated Appropriations Act
- Pharmacy Benefits Manager Accountability Act
- Cami Agena, JD - Attorney, The Phoenix Law Group, LLC
- Suzanne Broderick, JD - Attorney, The Phoenix Law Group, LLC
9:45am - 10:30amFree
The Latest on 340B Drug Pricing Program
Part 1: Fireside Chat: PROTECT 340B Act
Everything we need to know surrounding the PROTECT 340B Act
- Bob Charles - Principal/Founder, The Generisys Company
- Ann O'Brien - Vice President, Consultant Relations, Prime Therapeutics
10:30am - 11:00am
Morning Networking and Refreshment Break
11:00am - 11:45amFree
Overview of the Average Manufacturer Price (AMP) Cap Removal Project in Relation to Insulin and Rebates
- Why did some insulin manufacturers reduce their list prices and eliminate rebates?
- Will other manufacturers follow suite?
- Discuss the AMP Cap removal Project as part of the American Rescue Plan Act
- Address insulin manufacturers recent announcement of insulin price reductions and other market implications
- Andrew Timcheck, CERA, FSA, MAAA - Senior Consulting Actuary, Milliman
- Hiram Satterwhite, FSA, MAAA - Senior Consulting Actuary, Milliman
11:45am - 12:30pmFree
Fireside Chat: Rebates - What Are We Doing?
- If we can’t get rid of rebates, how can we get cheaper therapeutics into the hands of the consumer and who should be paying?
- Discuss how rebates will price with biosimilars
- Analysis of the economics and downstream consequences of rebates
- Tyrone Squires, CPBS - Managing Director, TransparentRx
12:30pm - 1:30pm
Networking Lunch in the Exhibit Hall
1:30pm - 2:15pmFree
Part Two: Resolving 340B challenges Through Innovative Market-Driven Solutions
The value of a 340B Clearinghouse to all relevant stakeholders.
Moving 340B discount administration from a direct purchase option to a rebate option
- Mesfin Tegenu - CEO and Chairman, RxParadigm
2:15pm - 3:00pm
Combatting Spread Pricing with Optimal PBM Contracting and Pricing
- Spread pricing: what it is, how does it impact claim pricing, and examples
- Assessing the impact of spread pricing…how to compare your pricing to competitive values
- The value of benchmark schedules such as NADAC
- RFP and contracting strategies
- Legislative initiatives: requirements and likely impact on the market
- Oral specialty generics: a high impact factor in future generic costs
- Summary: Maximizing Value in Generic Drugs: Now and the Future
- Terrance Killilea, PharmD - Partner, Senior Vice President, Clinical, Fiscal Integration, USI Insurance Services
3:00pm - 3:45pm
The Expanding Role of Data
- What the role of data means for patient insights and cost of care management
- Drive collaborative market access innovation through data and analytics exchange
- Looking ahead: how to utilize data when optimizing patient access in 2024
- Paul Dempsey - National Account Director, Obesity, Novo Nordisk
- Wes Smith, FSA, CERA, MAAA - Vice President, Analytics and Reporting, AffirmedRx
3:45pm - 4:45pm
Reception
Filter
Free / Premium
Choose Day